UNSPSC 51313507: Elbanizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S39YD087F9, chemically known as 1-(2-((2,6-dimethyl-3-nitro-4-pyridyl)amino)ethyl)-4-(diphenylmethyl)piperazine. but generally known as elbanizine, which bears US NIH Compound Identifier 208913. European Medicines Agency schedules Elbanizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06478MIG.

UNSPSC 51313507 Elbanizine, a Commodity code, does not align with the pharmaceutical procurement activity actually appearing in recent state and local solicitations. The code nominally refers to a specific chemical compound used in pharmaceutical manufacturing, yet the recent opportunities tagged under this code document the procurement of finished pharmaceutical products—naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs—rather than raw pharmaceutical ingredients or active pharmaceutical ingredients (APIs). The mismatch suggests either a classification error in the source data or a significant drift between the code's intended scope and how state and local procurement offices are applying it in practice.

The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-jurisdictional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). Representative recent solicitations include Seminole County's IFB60459723LAS (closing July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment; and MMCAP's S1070000015802 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026. Geographic activity is concentrated in Florida, Texas, and Minnesota. Given the code's apparent misalignment with finished pharmaceutical procurement, this code shows little relevant recent activity for vendors specializing in the chemical compound itself.